| Exclusion Criteria: | 1) Patients on enzyme-inducing anti-epileptic drugs within 2 weeks prior to randomisation. - Note: Patients are eligible if they switched to non-enzyme inducing agents and discontinued enzyme-inducing agents for more than or equal to 2 weeks prior to randomisation.
2) Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count </=1.5 x 10^9 /L or platelet count </=100 x 10^9 /L or requiring regular blood transfusions to maintain haemoglobin >9g/dL
3) Serum bilirubin >/=1.5 x ULRR(except for patients with known documented cases of Gilbert's Syndrome)
4) ALT or AST >/= 2.5 x ULRR
5) Serum creatinine > 1.5 x ULRR or a creatinine clearance of </= 50mL/min calculated by Cockcroft-Gault
6) Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein < 1.5g in a 24 hr period or UPC ratio <1.5
7) History of significant gastrointestinal impairment including malabsorption disorders due to structural defects such as post-gastrectomy, radiation enteritis, congenital or acquired reduction in absorptive surface, etc., as judged by the Investigator, that would significantly affect the absorption of AZD2171, including the ability to swallow the tablet whole
8) Patient with a history of poorly controlled hypertension with resting blood pressure > 150/100mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy, or patients who are requiring maximal doses of calcium channel blockers to stabilise blood pressure
9) Any evidence of severe or uncontrolled diseases (eg, unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
10) Unresolved toxicity > CTCAE grade 1 from previous anti-cancer therapy (including radiotherapy) except alopecia (if applicable)
11) Mean QTc with Bazetts correction >470msec in screening ECG or history of familial, long QT syndrome
12) Significant haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks)
13) Recent (<14 days) major thoracic or abdominal surgery or brain biopsy. Recent craniotomy(<28 days) prior to first dose, or a surgical incision that is not fully healed
14) Pregnant or breast-feeding women or women of childbearing potential with a positive pregnancy test prior to receiving study medication
15) Known hypersensitivity to cediranib or any of its excipients
16) History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the subject has been disease free for 2 years and they have tissue diagnosis of the target lesion.
17) Known active infection with hepatitis B or C or HIV
18) Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
19) Previous enrolment or randomisation of treatment in the present study.
20) Treatment with an investigational drug within 30 days prior to the first dose of cediranib
21) Other concomitant anti-cancer therapy except steroids
22) Previous anti-angiogenesis (eg bevacizumab, sorafenib, sunitinib) therapy
23) Patients with evidence of any intratumoral or peritumoral haemorrhage deemed significant by the treating physician
24) Patients who have received any form of cranial radiation within 3 months prior to study entry.
25) Known hypersensitivity to lomustine or any of its excipients
26) Patients with a baseline below 70% of the predicted Forced Vital Capacity (FVC) or Carbon Monoxide Diffusing Capacity (DLCO). However, patients with values less than these for either FVC or DLCO may still be eligible for enrolment provided that lung pathology has been excluded after a full consultation by a pulmonologist including additional tests, for example: a high resolution CT scan
27) Patients who have progressed within 3 months of completion of standard cranial radiation
28) Patients that have received radiosurgery or brachytherapy
29) Patients with Celiac Disease |